Transforming Alkermes into a Global Biopharmaceutical Company Case Solution
In the summer of 2011, Jim Frates, CFO of Alkermes faced choices about the best way to invest the assets of Dublin, Ireland-based Elan Drug Technologies (EDT) – a deal which was anticipated to narrow the fall.
The case describes the history of Alkermes, provides information about the planned combiner, and explains the financing options. The case gives pupils the chance to assess the attractiveness of the merger to assess the function CFOs play in biopharmaceutical businesses, and to choose a funding option.
This is just an excerpt. This case is about FINANCE & ACCOUNTING
PUBLICATION DATE: May 28, 2015 PRODUCT #: 215079-PDF-ENG
How We Work?
Just email us your case materials and instructions to firstname.lastname@example.org and confirm your order by making the payment here